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Degradative enzyme activity has been shown to be elevated in many diseases 
including shock, diabetes, schizophrenia, several types of cancers, and coagulation 
disorders. The ability to measure degradative enzyme activity in whole blood and other 
complex samples would be useful for the development of rapid clinical diagnostics, the 
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elucidation of disease progression, and the design of therapeutics. Current techniques to 
measure degradative enzyme activity require considerable amounts of time and sample 
processing steps. In this dissertation, a novel method for rapid detection of degradative 
enzyme activity, specifically protease activity, in whole blood is applied to several disease 
states: diabetes, schizophrenia, and premature neonates. 
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Abstract 
 Degradative enzymes are critical to the physiological homeostasis of a healthy 
organism. Deregulation of the activity of degradative enzymes is associated with a variety 
of diseases. Two important classes of degradative enzymes are proteases and lipases. 
Proteases degrade proteins by cleaving peptide bonds, whereas lipases degrade lipids by 
cleaving ester bonds. Deregulation of the activity more than the concentration of these 
enzymes is indicative of a  diseased state. Available methods for detecting activity of 
proteases and lipases require sample processing and are unable to be deployed at the point-
of-care. This dissertation reports the use of novel charge-changing substrates for the 
detection of protease and lipase activity in whole blood without the need for sample 
preparation. 
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1.1 Degradative enzymes 
Degradative enzymes comprise classes of enzymes responsible for degrading 
substances endogenous and exogenous to an organism. Degradative enzymes are involved 
in numerous physiological and pathological processes. This dissertation will focus on two 
classes of degradative enzymes: proteases and lipases. 
1.2 Proteases 
Proteases are the efficient nanomachines responsible for the hydrolysis of peptide 
bonds and therefore the degradation of proteins. Most proteolytic enzymes cleave α-peptide 
bonds between naturally occurring amino acids [1]. There are some notable exceptions, but 
these proteolytic enzymes are beyond the scope of this dissertation. According to the 
Degradome Database, over 500 human proteases exist. Thousands more proteases are 
found in animals, microorganisms, and plants [26]. 
 
1.2.1 Significance of proteases 
Proteases are involved in many physiological and pathological processes. Any 
deregulation of proteolytic enzyme activity may lead to a variety of pathological processes, 
from minor to catastrophic and from chronic to acute. Deregulation of proteolytic enzyme 
activity has been shown to be a component of a wide range of diseases, from cancer to 
chronic inflammatory diseases such as rheumatoid arthritis [17]. The association of their 
activity with disease and their defined structure have made proteases not only attractive 
objects of study for researchers trying to elucidate the pathophysiology of various diseases 
but also attractive targets for pharmaceutical companies. 
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1.2.2 Structure and classification of proteases 
Proteases may be divided into six classes according to their catalytic mechanism: 
aspartic, glutamic, metallo, cysteine, serine, and threonine proteases. Glutamic proteases 
have not yet been reported in mammals [24]. For the catalytic process of peptide bond 
hydrolysis, the aspartic, glutamic, and metalloproteinase enzymes use a water molecule as 
nucleophile while the others (cysteine, serine, and threonine proteases) use an amino acid 
containing a nucleophilic side chain according to their respective classification name [16]. 
Metalloproteinases, as the name implies, require a Zn2+ ion to polarize a water molecule to 
function as a nucleophile to catalyze hydrolysis of the scissile peptide bond of the substrate 
[31]. 
 
1.2.3 Regulation of protease expression and activity 
Proteolytic activity is tightly regulated in vivo by multiple mechanisms. Organisms 
control these potent enzymes by regulating gene expression, compartmentalizing enzymes 
in cellular and/or extracellular space, activating inactive precursors, and inhibiting the 
active enzyme with endogenous inhibitors. Expression of genes encoding proteases is 
controlled by growth factors, hormones, cytokines, and physical stress [33]. Proteolytic 
enzymes are synthesized as inactive precursors (also called pro-enzymes or zymogens) to 
prevent unregulated protein degradation. Removal of a portion of the inactive precursor by 
limited proteolysis produces the active enzyme and usually occurs within the subcellular 
compartment or extracellular space in which the active enzyme exerts its biological 
function [10]. In general, conversion of inactive precursors to active enzymes is irreversible 
and so organisms possess inhibitors to deactivate the active enzymes [9].  
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1.2.4 Function of proteases 
One of the most important distinguishing features of a protease is its specificity: 
where it will cleave a substrate protein or peptide. The cleavage specificity of a protease 
dictates the peptide and protein substrates it is capable of cleaving efficiently and thus 
determines its role in vivo. Depending on their function in an organism, proteases range 
from highly particular to promiscuous in their cleavage requirements. For example, 
thrombin is a coagulation protease that is highly specific in its cleavage preferences, which 
reflects the importance of maintaining homeostasis between bleeding and clotting [7]. On 
the other hand, the proteases released by the pancreas are promiscuous in their cleavage 
preferences, reflecting the need of an organism to be able to digest the diversity of proteins 
it ingests [34]. 
1.3 Autodigestion hypothesis: proteases 
What prevents auto-digestion of the intestine by digestive enzymes? Pancreatic 
proteases are secreted into the intestine as active enzymes. These proteases are capable of 
breaking down almost all proteins as a requirement of digestion. The wall of the intestine 
does not contain sufficient concentrations of endogenous enzyme inhibitors to prevent 
auto-digestion. Protection of the intestinal wall from these potent digestive enzymes 
appears to be provided by the barrier of the mucosal epithelium lining the intestinal wall, 
which compartmentalizes the proteases in the intestinal lumen where they are restricted to 
digesting only the contents of the intestine [28, 29]. 
 Under normal physiological conditions, the mucosal layer lining the intestinal wall 
prevents the escape of pancreatic proteases. However, disruption of the mucosal barrier 
releases the pancreatic proteases into the intestinal wall and the systemic circulation, 
	 6 
leading to organ failure, blood pressure reduction and mortality within hours [11]. While 
shock is characterized by this catastrophic release of digestive enzymes, various chronic 
diseases, e.g. hypertension and diabetes, may also be characterized by release of pancreatic 
proteases but to a milder degree [30].  
The unchecked proteolytic activity that reaches the circulation in chronic diseases 
is much lower than that in shock, but it is sufficient to produce cell dysfunctions. In the 
spontaneously hypertensive rat (a genetic model of hypertension) proteolytic cleavage of 
the insulin receptor ectodomain leads to hyperglycemia and insulin resistance [5]. There is 
a need for sensitive detection of circulating protease activity and further exploration of 
proteolytic degradation of cell surface receptors in chronic human diseases such as 
diabetes. 
1.4 Analysis of proteases in biological fluids: activity-based assays 
Due to the tight regulation of degradative enzyme activity in vivo, measurement of 
enzyme activity is more meaningful than enzyme concentration for the monitoring of 
biological or pathological processes. There is a need for simple and robust methods for 
protease activity detection in biological fluids. Activity of degradative enzymes in 
biological fluids might be analyzed by two main approaches. The first is based on the use 
of substrates while the second is based on the use of inhibitors. Substrate-based assays 
usually require radioactive or fluorescent measurements for monitoring the activity of 
degradative enzymes while inhibitor-based assays make use of synthetic enzyme inhibitors 
that target the active site and can be used to enrich or tag active degradative enzymes in an 
activity dependent manner. Assays that study degradative enzyme activity in vivo are 
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outside the scope of this dissertation. Assays that indirectly study degradative enzyme 
activity by measuring degradation products are also outside the scope of this dissertation. 
1.4.1 Substrate-based activity assays 
Radiolabeled substrates used to be used before assays that bypassed the need for 
radioactive material became available. Radiolabeled substrates were incubated with 
samples and cleavage products were separated from non-digested proteins by protein 
precipitation [15]. Zymography is a widely used method for matrix metalloproteinase 
(MMP) analysis. While zymography is a sensitive technique, it is not quantitative and it 
cannot distinguish between active and inhibited forms of the enzyme due to the 
denaturation and refolding of the enzyme during the protocol [36]. Activity-dependent 
ELISA assays are costly and specificity relies on antibody-enzyme recognition [4]. An easy 
but not very specific assay format relies on proteolytic cleavage of fluorescent peptide 
substrates (Figure 1.1A). The substrate peptides contain a fluorescent group which is 
quenched. Proteolytic cleavage of the substrate unquenched the fluorophore [23]. This 
assay is a very useful tool for monitoring the activity of purified proteases but is 
inappropriate in biological samples that attenuate the fluorescent signal. 
1.4.2 Inhibitor-based activity assays 
While the success of synthetic protease inhibitors in clinical applications has been 
limited, analytical techniques based on derivatives of synthetic protease inhibitors have had 
success [32]. Activity-based probes (ABP) target active proteases in a family-wide manner, 
for example in biological fluids, before proceeding to downstream analyses. Downstream 
analyses are necessary to identify which particular proteases within a targeted family were 
tagged by the ABP strategy [6]. 
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1.5 Novel assay for protease activity detection 
Available protease activity detection methods may be rapid and sensitive but only 
in buffers or after the sample has been processed into plasma or serum. These available 
methods are not suitable for the direct measurement of protease activity in whole blood 
because of the strong autofluorescence, background absorption, and light scattering 
resulting from the various components of blood. 
1.5.1 Issue of sample preparation 
Protease activity assays generally overcome the fundamental limitation of blood 
quenching or obscuring label signals by performing various sample preparation steps, 
including centrifugation, dilution, and the addition of anticoagulants and other additives. 
These processing steps alter the concentrations and activities of proteases in blood, 
reducing the likelihood of the assay reflecting the physiological state of the sampled patient 
(Figure 1.2). 
Sample preparation also increases the time, cost, labor requirements and overall 
complexity of the assay (Figure 1.2). The need to draw milliliters of blood to process into 
plasma precludes these assays from any POC applications. POC tests are generally cheaper, 
faster, more efficient and provide results for routine analysis in minutes, while tests carried 
out in central clinical laboratories require many hours or, in some cases, days before a result 
is available. It is important to eliminate sample preparation and to measure protease activity 
directly in a whole blood sample to enable timely treatment decisions, especially in time-
critical medical situations. 
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1.5.2 Whole blood assay for protease activity detection 
The assays used in this dissertation were developed by Lefkowitz et al. [12–14] and 
Modestino et al. [21] to bypass sample preparation. The assays are based on the 
electrophoretic separation of charge-changing peptide substrates from whole blood 
(Figure 1.1B, Figure 1.3). Negatively charged or neutral fluorescently-labeled peptide 
substrates produce positively charged fluorescent products upon cleavage by a target 
protease after an incubation period in microliters of whole blood. The fluorescent positively 
charged cleavage product can be separated by application of an electric field from the 
components of whole blood, the vast majority of which are negatively charged. Thus, this 
method allows fluorescent signal produced from protease activity to be rapidly resolved 
from blood and detected. 
1.6 Lipases 
Lipases are enzymes that degrade fats by hydrolyzing ester bonds. Lipases are 
interfacial catalysts, rarely acting on substrates in true solution [27]. 
1.6.1 Significance of lipases 
Lipolytic activity results in the release of free fatty acids (FFAs). FFAs are utilized 
for energy production in the muscle or are re-esterified for storage in the adipose tissue [3]. 
Hydrolysis of triglycerides (TGs) is essential for energy storage and utilization, whereas 
variations in TG/FFA levels have a variety of clinical implications that have been 
extensively reviewed. Deregulation of lipolytic activity is implicated in the invasion of 
tissues by microorganisms, hyperlipidemia or procoagulant state, and conditions ranging 
from obesity to cystic fibrosis [25, 35]. 
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1.6.2 Structure and classification of lipases 
Lipases can be divided into triacylglycerol lipases and phospholipases. 
Phospholipase catalyzes the hydrolysis of phospholipids. Phospholipase A catalyzes the 
hydrolysis of phospholipids to free fatty acid and lysophospholipid; phospholipases A1 and 
A2attack ester bonds in positions 1 and 2 of the phospholipid respectively. Phospholipase 
B catalyzes the generation of free fatty acid and glycerylphospholipid, and phospholipase 
C catalyzes the generation of diacylglycerol and a phosphoryl base [2]. 
The human lipases include the pre-duodenal lingual and gastric lipase and the extra-
duodenal pancreatic, hepatic, lipoprotein, and endothelial lipases [22]. 
1.6.3 Regulation of lipase expression and activity 
Whereas numerous exogenous lipase inhibitors have been characterized, mainly 
representing plant derived components such as saponins, polyphenols, and terpenes, only 
a limited number of endogenous inhibitors of lipases have been identified [19]. Unlike 
pancreatic proteases, pancreatic lipases are secreted in their final active form. 
1.6.4 Function of lipases 
Dietary triglycerides (TGs) contribute a major portion of our daily energy 
requirement. TGs are digested in the gastrointestinal tract through the action of several 
lipases including lingual lipase and gastric lipase. However, the majority of dietary TGs 
are digested in the small intestine by pancreatic lipase (PL) assisted by pancreatic colipase, 
pancreatic lipase-related protein 2, and carboxyl ester lipase. Lipoprotein lipase (LPL) is 
the enzyme responsible for controlling plasma TG levels [18]. 
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1.7 Autodigestion hypothesis: lipases 
Containment of the digestive process in the lumen of the small intestine requires an 
intact mucosal barrier. Compromise of this barrier allows leakage of digestive enzymes 
into the intestinal wall and the circulation, leading to tissue damage termed ‘autodigestion.’ 
Lipases generate cytotoxic fragments, e.g. unbound free fatty acids, and the entry of these 
cytotoxic fragments into the systemic circulation generate multiple cell dysfunctions in 
other organs [28–30]. More sensitive and specific diagnostic tools to detect lipase activity 
in patients are required.  
1.8 Analysis of lipases in biological fluids: activity-based assays 
The available lipase assays have limitations for the determination of lipase activity 
in biological fluids. The conventional radiometric assay, using 3H- or 14C-labeled trioleoyl 
glycerol as substrate, requires separation of the released labeled free fatty acids (FFAs), is 
time-consuming with low throughput, and is limited to research applications due to the 
environmental concerns associated with the radiolabel [20]. Fluorescence-based assays 
using coumarin derivatives are attractive because they fluoresce only after conversion to 
lipolytic products. However, the derivatives are unstable, requiring frequent substrate 
preparation, and are hydrolyzed nonspecifically by enzymes other than LPL [8]. In 
addition, these fluorescence-based assays are unable to be performed in whole blood due 
to the quenching of fluorescent signal by the components of blood. Another commonly 
used assay, the titrimetric method, is not sufficiently sensitive to be clinically useful [8]. 
1.9 Novel assay for lipase activity detection 
 This dissertation reports the development of a novel assay for the detection of lipase 
activity in whole blood. The simplicity of the assay make it ideal for monitoring of lipase 
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activity in the clinical setting as well as screening for screening for inhibitors and activators 
of lipases, thus expediting discovery of drugs of potential clinical value. 
1.9.1 Issue of sample preparation 
Lipase activity assays generally overcome the fundamental limitation of blood 
quenching or obscuring label signals by performing various sample preparation steps, 
including centrifugation, dilution, and the addition of anticoagulants and other additives. 
These processing steps alter the concentrations and activities of proteases in blood, 
reducing the likelihood of the assay reflecting the physiological state of the sampled patient 
(Figure 1.2). 
Sample preparation also increases the time, cost, labor requirements and overall 
complexity of the assay (Figure 1.2). The need to draw milliliters of blood to process into 
plasma precludes these assays from any POC applications. POC tests are generally cheaper, 
faster, more efficient and provide results for routine analysis in minutes, while tests carried 
out in central clinical laboratories require many hours or, in some cases, days before a result 
is available. It is important to eliminate sample preparation and to measure protease activity 
directly in a whole blood sample to enable timely treatment decisions, especially in time-
critical medical situations. 
1.9.2 Whole blood assay for lipase activity detection 
 This dissertation reports the development of a novel assay for the detection of lipase 
activity in whole blood based on charge-changing phospholipid substrates (Chapter 5). 
The fluorescently labeled phospholipid substrates are initially negatively charged and upon 
cleavage by a target lipase after an incubation period in whole release a positively charge 
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free fatty acid (FFA) that may be rapidly separated from the negatively charged 
components of whole blood by the application of an electric field. 
1.10 Scope of the dissertation 
The overall goal of this dissertation was the design and implementation of 
innovative techniques for the detection of degradative enzyme activity in complex patient 
samples. The focus of this dissertation was on in vitro instead of in vivo methods for 
enzyme activity measurement as well as on clinical rather than industrial applications of 
these detection techniques. 
Chapter 2 of this dissertation describes the use of protease activity assays based 
on charge-changing substrates in a pilot study involving diabetic patients, prediabetic 
patients, and healthy volunteers. 
Chapter 3 discusses the use of protease activity assays based on charge-changing 
substrates in a pilot study involving schizophrenia patients and healthy volunteers. 
Chapter 4 describes the use of protease activity assays based on charge-changing 
substrates in a pilot study involving neonates with various conditions affecting 
gastrointestinal health and coagulation balance. 
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Figure 1.1. Conventional FRET substrates versus novel charge-changing substrates 
for protease activity detection. (A) FRET substrates for protease activity detection 
comprise a peptide containing an appropriate cleavage site for the protease of interest, a 
quencher, and a fluorophore that is quenched until cleavage of the peptide substrate by the 
protease of interest increases the distance between the quencher and fluorophore. FRET 
substrates must be run in plasma since whole blood attenuates fluorescence and the need 
for plasma necessitates milliliters of blood to be drawn, precluding point-of-care 
applications. (B) Charge-changing substrates for protease activity detection comprise a 
peptide containing an appropriate cleavage site for the protease of interest, charged amino 
acids or other charged moieties, and a fluorophore or other label. The substrate is initially 
negatively charged or neutral and upon cleavage produces a positively charged cleavage 
product with a fluorophore or other label that can be electrophoretically separated from the 
components of whole blood and detected. Only microliters of whole blood are necessary 
and so use at the point-of-care is possible. 
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Figure 1.2. Sample processing of conventional activity assays. Conventional assays for 
the detection of protease or lipase activity are unable to be performed in whole blood due 
to the components of blood quenching the signal of fluorophores or obscuring other labels. 
Blood must be centrifuged into plasma, necessitating milliliters of blood to be drawn from 
a vein, which in turn requires a trained phlebotomist and precludes the development of a 
point-of-care device for the assay. Blood is not used immediately in assays at the point-of-
care and so must be drawn into tubes with anticoagulants before being centrifuged into 
plasma or allowed to coagulate to produce serum. Plasma or serum may need to be further 
altered by dilution or additives before use in an assay. These processing steps add time, 
cost, risk of human error, and manipulation of the sample, frustrating the desire for assays 
of samples to reflect the true physiological condition of the patient. 
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Figure 1.3. Whole blood assay for protease activity detection. (A) Incubation of 
microliters of whole blood with charge-changing fluorescently labeled peptide substrates 
designed to be cleaved by the target protease and release a positively charged fluorescently 
labeled cleavage product. (B) Application of an electric field separates the positively 
charged fluorescently labeled cleavage product from the negatively charged components 
of blood. Note the reversed polarity of the gel electrophoresis setup. (C) Separation by gel 
electrophoresis of the positively charged fluorescently labeled cleavage product from the 
negatively charged components of blood concentrates the fluorescent signal for detection. 
The measured fluorescent signal indicates protease activity. 
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Abstract 
Protease activity and intestinal permeability have been identified as contributing 
to the pathogenesis of insulin resistance in type 2 diabetes mellitus (T2DM). In this study 
we investigate protease activity and insulin receptor cleavage in T2DM, and the effect of 
a single high-calorie, - fat, and -sugar meal on them, as a way to elucidate the relationship 
between over-nutrition, intestinal permeability, protease activity in circulation, and 
insulin receptor cleavage. We utilize a new method for detection of protease activities 
directly in fresh whole human blood samples. Pre-meal activity levels of MMP-2/-9- and 
elastase-like in the blood of T2DM and pre-T2DM patients were significantly elevated 
compared to normal volunteers (p<0.01). Peripheral blood mononuclear cells (PBMC) 
incubated with plasma from T2DM and pre-T2DM showed a significant lowered density 
of insulin receptor, when compared to PBMCs incubated with control plasma. No 
significant difference was found in trypsin-like activity, inflammatory markers and 
soluble adhesion molecules between control, T2DM, and pre-T2DM. An initial 
postprandial elevation in protease activity, inflammatory biomarkers, and soluble 
adhesion molecules was observed in control participants. The insulin receptor density in 
PBMCs incubated with plasma collected from control participants after the meal, showed 
a significant reduction when compared to the cells incubated with baseline plasma. The 
results presented in this study suggests that chronic over nutrition produces chronic 
elevation of proteases in circulation, which in turn may cleave the insulin receptor, and 
induce insulin resistivity.  
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2.1 Introduction 
Type 2 diabetes mellitus (T2DM) is an inflammatory disorder characterized by 
hyperglycemia and insulin resistance [1,2]. T2DM requires long-term medical care, 
posing a significant burden on the healthcare system. Despite the high prevalence of 
T2DM, a satisfactory molecular mechanism for the development of insulin resistance has 
not yet been defined [3]. This incomplete understanding limits the development of more 
efficient treatment and prevention strategies. In this study we investigate the effect of a 
meal on circulatory proteolytic activity and on insulin receptor ectodomain density of 
peripheral mononuclear blood cells (PBMCs) after incubation with plasma collected 
before and after the meal. The overall aim of this pilot study is to determine if proteases 
link over-nutrition with the development of insulin resistance in T2DM.  
Unchecked protease activity contributes to the development of insulin resistance. 
In the spontaneous hypertensive rat, proteolytic cleavage of the extracellular domain of 
the insulin receptor leads to insulin resistance [3]. Enteral blockade of digestive proteases 
prevents acute insulin resistance after hemorrhagic shock [4]. Other studies have 
demonstrated elevation of soluble insulin receptor in the plasma of T2DM patients [5], 
and the proposed mechanism for insulin receptor cleavage is the proteolytic action of a 
calcium-dependent protease [6].  
Increased intestinal permeability may increase proteolytic activity by allowing 
powerful digestive enzymes to leak out of the intestinal lumen into the systemic 
circulation. In T2DM, the intestinal barrier has a mild but chronic increase in 
permeability [7]. Chronic over-consumption of a high-fat, high-sugar diet is the main risk 
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factor for the development of T2DM; this diet is also believed to increase the 
permeability of the intestinal mucosa [8]. Thus we hypothesize that T2DM patients have 
increased proteolytic activity in circulation due to an increased intestinal permeability; 
this increase in proteolytic activity may trigger insulin resistance by proteolytic cleavage 
of the insulin receptor.  
Despite the link between proteases and insulin resistance, few studies have 
measured protease activity in the circulation [9]. Previous efforts to study proteases in 
T2DM have yielded conflicting results and have focused on MMP-2 and MMP-9 levels 
in plasma. These measurements were carried out under a set of limitations, including the 
need to isolate blood cells and plasma, low sensitivity, time-consuming steps, and 
relatively large sample volume.  
In this study we used a new electrophoretic technique developed in our laboratory 
that uses charge-changing fluorescent peptides capable of detecting nanomolar 
concentrations of active proteases in a single drop of whole blood without the need for 
sample preparation [10-12]. We measured the activities of the pancreatic proteases, 
trypsin and elastase, and of the metalloproteases, MMP-2 and -9, in unseparated fresh 
whole blood of T2DM, p-T2DM and control participants. We examined the effect of a 
high-calorie, -fat and -sugar meal on protease activity in the circulation to elucidate the 
relationship between the meal, intestinal permeability, and circulating protease activity. 
We also measured the insulin receptor density in PBMCs incubated with plasma from 
T2DM, p-T2DM and control participants collected pre- and post-meal. The overall 
purpose is to determine if protease activity in the circulation is responsible for clipping 
 24 
the extracellular domain of the insulin receptor, generating insulin resistance and 
compromised glucose management. Furthermore, we determined the postprandial levels 
of serum amyloid-A (SAA), soluble adhesion molecules (sICAM-1 and sVCAM-1) as 
well as an inflammatory marker, C-reactive Protein (CRP), in T2DM, p-T2DM and 
control participants over the same time period.  
2.2 Results  
2.2.1 Study Participants 
A total of 34 participants were enrolled and consented in this pilot study, 
including 14 controls subjects without T2DM, whose measurements served as 
comparison with the data from participants with T2DM. Four groups were formed: 
participants with diabetes (T2DM, n=10); with pre-diabetes (p-T2DM, n=10); control (C, 
n=11); and control that fasted during the whole experiment (Cf, n=3). From the 11 C-
group, values for four participants were discarded because their metabolic syndrome 
index (MSI) was between 3 and 5, and thus were not considered true controls for this 
study.  
No significant differences were found between the baseline values for control and 
control fasting groups (Table 2.1). The body weight was significantly higher in T2DM 
when compared to control (Table 2.1, p<0.05,), and to control fasting participants (Table 
2.1, p<0.001), while it was significantly higher for p-T2DM when compared only to Cf 
(Table 2.1, p<0.05). The waist circumference and BMI were significantly higher in both 
T2DM, and p-T2DM when compared to control fasting group (Table 2.1, p<0.05), but 
not for the control participants. The fasting glucose levels were significantly higher in 
T2DM when compared to all other groups (Table 2.1, p<0.001). The systolic blood 
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pressure (SBP) was significantly higher in T2DM compared to control (Table 2.1, 
p<0.05) and control fasting participants (Table 2.1, p<0.001). Finally, the MSI was 
significantly higher for p-T2DM (Table 2.1, p<0.05) and T2DM (Table 2.1, p<0.001) 
compared to control fasting, while only significantly higher for T2DM compared to 
control participants (Table 2.1, p<0.05). 
2.2.2 Circulating protease activity 
Elevated baseline elastase and MMP2/9-like activity in PT2DM and T2DM 
We detected elevation in baseline MMP-2/-9-like, and elastase-like activities in 
T2DM, and p-T2DM, when compared to control (Figure 2.3A-B, p<0.05), and control 
fasting participants (Figure 2.3A-B, p<0.001). While there are differences in the baseline 
values of the trypsin-like activity between groups, no statistically significant difference 
between the groups was seen (Figure 2.3C).  
Calibration curves using the specific fluorescent substrates and spiked proteases 
were obtained to determine the range of activity observed in each of the groups (Figure 
2.3D-F). For trypsin the activity detected in circulation ranges between approximately 
5.4nM for control fasting and 26.8nM for controls (Figure 2.3D); for elastase it ranges 
from approximately 9.8nM for control fasting, to 37.2nM for T2DM (Figure 2.3E); for 
MMP2/9-activity it ranges from approximately 5.4nM for control fasting to 54.1nM for 
T2DM (Figure 2.3F).  
At baseline, for control participants, we detected a strong positive linear 
correlation between elastase-like activity and age, waist, BMI, and SBP (Figure 2.8A, 
p<0.05). MMP-2/-9-like baseline activity had only a strong positive relation with baseline 
SBP for control participants (Figure 2.8A, p<0.05). Trypsin-like activity has a strong 
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positive linear relation with BMI (Figure 2.8A-B, p<0.05), and moderate positive linear 
relation with waist circumference (Figure 2.8A, C, p<0.1).  
Initial postprandial increase in circulatory protease activity in control participants  
The protease activity in plasma of control participants for MMP-2/9-like, elastase-
like, and trypsin-like activities increased significantly already at 15 min after the meal 
(Figure 2.4A-C, p<0.05).  The T2DM group also showed an increase in elastase-like 
activity 15 minutes after the meal (Figure 2.4E, p<0.05). We detected a strong positive 
correlation between blood glucose during the meal and  MMP-2/-9-like activity (Figure 
2.4G, p<0.0001), elastase-like-activity (Figure 2.4H, p<0.0001), and trypsin-like-activity 
(Figure 2.4I, p<0.0001).  
Insulin receptor density reduction in PBMC after incubation with plasma 
We found that cells incubated with plasma from T2DM, and p-T2DM had 
significant lower levels of insulin receptor density compared to those incubated with 
plasma from control participants (Figure 2.5A, p<0.0001). In addition, there was a 
significant decrease in insulin receptor density in cells incubated with plasma from all 
groups compared to cells incubated with 1XPBS (Figure 2.5A, p<0.0001). Cells 
incubated with T2DM plasma also showed significant lower levels of insulin receptor 
density when compared to cells incubated with p-T2DM plasma (Figure 2.5A, p<0.05).   
The insulin receptor density in PBMC incubated with plasma collected at 
different time points from fasting control participant remained the same throughout the 5-
hour observation period (Figure 2.5B). In contrast, the insulin receptor density in PBMC 
incubated plasma collected after a meal from control participants decreased significantly 
in cells incubated with plasma collected 45minutes after the meal (Figure 2.5C, p<0.01). 
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The insulin receptor density in cells of p-T2DM also decreased significantly when they 
were incubated with plasma collected at 30 and 60minutes after the meal (Figure 2.5D, 
p<0.01). For T2DM, although the insulin receptor density decreased in cells incubated 
with plasma collected 60 minutes after the meal, no statistically significant change was 
found. 
Incubation of PBMC with plasma from control participants 45minutes after the 
meal caused a decreased in insulin receptor density in PBMC (Figure 2.9A), an effect 
that was larger when the cells were incubated for a longer period of time. We also 
showed that incubation of PBMC with 5nM of purified trypsin, elastase, and MMP-2 
spiked into 1XPBS produced a significant decrease in insulin receptor density on the cell 
membrane (Figure 2.9B). 
2.2.3 Inflammatory markers and soluble adhesion molecules 
Baseline inflammatory markers and soluble adhesion molecules 
Baseline levels of inflammatory markers, and soluble adhesion molecules differed 
between the groups. The difference in CRP baseline value was only statistically 
significant between T2DM and control fasting group (Figure 2.6A, p<0.05); while SAA, 
sICAM-1, and sVCAM-1 baseline values in p-T2DM and T2DM were significantly 
higher than in control fasting group (Figure 2.6A-B, p<0.05).  
Initial postprandial increase in circulatory inflammatory markers and soluble adhesion 
molecules in control participants  
Inflammatory markers, and soluble adhesion molecules rose in the circulation of 
control participants after the meal (Figure 2.7). The CRP values increased significantly at 
times 45 and 60 minutes (Figure 2.7A, p<0.05), while the SAA values rose significantly 
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at times 45, 60, and 120 minutes after the meal (Figure 2.7B, p<0.05). The sICAM-1 
values increased significantly at 45 and 120 minutes (Figure 2.7C, p<0.05), while the 
sVCAM-1 rose at times 45, 60 and 120 minutes after the meal (Figure 2.7D, p<0.05). 
We detected a strong negative correlation between blood glucose and plasma CRP levels 
(Figure 2.7I, p<0.0001), SAA (Figure 2.7J, p<0.0001), sICAM-1 (Figure 2.7K, 
p<0.0001), and sVCAM-1 (Figure 2.7L, p<0.0001).  
2.3 Discussion 
Digestive enzymes may be driving one mechanism of T2DM development. 
Chronic over-nutrition is central to the development of T2DM. Intestinal permeability is 
a key factor in the development of insulin resistance and T2DM [7-8,13]. Inside the 
lumen of the intestine, powerful pancreatic proteases, including trypsin and elastase, 
reside in the fully active state and degrade most biomolecules within hours as part of 
normal digestion. During a meal the concentration of pancreatic proteases increases 
inside the intestine, accompanied by an increase in intestinal permeability, enabling 
absorption of important nutrients from the intestine into the bloodstream [14]. We 
hypothesize that one mechanism leading to glucose sensitivity and T2DM is leakage of 
digestive proteases from the lumen of the intestine into the peripheral circulation due to 
chronic over-nutrition. Once these proteases reach the circulation, they can activate other 
proteases (e.g. metalloproteases) and cleave cellular receptors (e.g. insulin receptor), 
resulting in reduced insulin sensitivity and compromised glucose management and 
T2DM. 
We detected elevation of baseline values for MMP-2/-9 and elastase activity in 
the circulation of p-T2DM and T2DM participants. We showed that cells incubated with 
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plasma from T2DM had a significant decrease in membrane density of the insulin 
receptor ectodomain. After a meal there is an initial transient elevation of proteases, 
soluble adhesion molecules, and inflammatory markers in the circulation of control 
participants, which returns to normal values hours after the meal. We also present 
evidence of reduced insulin receptor density in cells incubated with plasma from control 
and p-T2DM after a meal, which links meal consumption with an elevation in protease 
activity, an increase in inflammatory state, a depletion of insulin receptor, and an increase 
in blood glucose.   
Protease activity in the circulation was measured using our novel electrophoretic 
assay, which enables protease activity detection in unprocessed whole blood (Figure 2). 
Limited data is available in the literature on plasma levels of proteases in T2DM. 
Previous efforts to study proteases in T2DM have yielded conflicting results and have 
focused mainly on MMP-2 and MMP-9 levels in plasma of T2DM. Some reports indicate 
no correlation between plasma levels of MMP-2 and -9 and T2DM [15]; others show 
elevated levels of MMP-2 and -9 in T2DM [16-18]; and one reports lower levels of 
MMP-2 and -9 after an oral glucose tolerance test for T2DM [19]. We believe that these 
discrepancies are due to the techniques used to measure protease activity and whether 
they were measured directly in whole blood or after separation of plasma and blood cells. 
Immunoassays, such as ELISAs, use antibodies that do not distinguish between the active 
and inactive forms of proteases; moreover, they require treated samples. Manipulation of 
blood samples introduces the possibility of error and loss of protease activity. The novel 
electrophoretic assay bypasses these limitations by: 1) detecting protease activity derived 
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from nanomolar levels of proteases; 2) detecting only active proteases; and 3) working 
with a small blood sample volume (3.5µL) [10-12]. 
The baseline elevation of MMP-2/-9 and elastase activity in T2DM (Figure 2.3A-
B) may be responsible for cleaving the insulin receptor extracellular domain and resulting 
in the poor blood glucose management of these patients.  Proteases, such as elastase, 
MMP-2 and MMP-9, are capable of not only re-shaping the extracellular matrix [20] and 
activating other proteases but also cleaving extracellular receptors [21-22]. We show that 
freshly isolated PBMCs incubated with plasma from T2DM or with purified proteases 
(MMP-2, elastase, and trypsin) exhibit a significant depletion of their insulin receptor 
density (Figure 2.5A and 2.9). We cannot rule out that the insulin receptor has been 
internalized by PBMCs, but the fact that cells incubated with proteases spiked into 
1XPBS also showed depletion of the insulin receptor (Figure 2.9) suggests that cleavage 
and not internalization of the insulin receptor is occurring. In addition, other groups have 
shown an elevation in soluble insulin receptor in T2DM plasma [5-6], and research in 
animal models suggests that insulin resistance is triggered by proteolytic cleavage of the 
insulin receptor [3].  
A major source of the increase in proteolytic activity in the circulation of T2DM 
may be the intestine. Chronic over-nutrition is a key driving force in the development of 
T2DM. We show that a single high-calorie/fat/sugar meal produces a significant initial 
increase in protease activity after meal consumption in control participants (Figure 2.4A-
C). The protease activity did not change significantly in control fasting participants 
(Figure 2.4A-C), suggesting that the increase of pancreatic proteases in the circulation is 
due to digestion. In control participants, the meal also caused an initial increase in soluble 
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adhesion molecules and inflammatory makers (Figure 2.7A-D) and an initial decrease in 
the insulin receptor density in cells incubated with plasma collected 45 minutes after the 
meal (Figure 2.5C). In contrast to control participants, T2DM had a significant initial 
increase in only elastase activity after the meal (Figure 2.4D-F) and no significant 
depletion in insulin receptor density (Figure 2.5E). T2DM participants are known to 
have elevated intestinal permeability [7-8] and have been shown by this study to have 
chronic elevated proteolytic activity in circulation (Figure 2.3), which may result in a 
reduced baseline insulin receptor density, making daily proteolytic activity and insulin 
receptor density fluctuations less pronounced than in healthy individuals.  
The initial elevation in elastase activity observed in T2DM might be caused not 
only by an increase in pancreatic elastase, which originates in the intestine, but also by 
neutrophil elastase, which increases in a state of inflammation [23]. In p-T2DM we show 
a decrease in the insulin receptor density of PBMC incubated with plasma taken 30 and 
60 minutes after the meal (Figure 2.5D). The measurements of the insulin receptor 
density were made using plasma from only three of the p-T2DM participants. Even if no 
significant post-prandial increase in proteolytic activity, inflammatory markers and 
soluble adhesion molecules was observed in the p-T2DM group (n=10), these three p-
T2DM participants showed a significant increase in proteolytic activity after the meal. 
This increase in postprandial proteolytic activity may be responsible for the decrease in 
insulin receptor density shown in PBMC and the increase in blood glucose levels (Figure 
2.5D). The strong positive correlation between protease activity and blood glucose levels 
(Figure 2.4G-I) suggests than an elevation in proteolytic activity is linked to 
uncontrolled blood glucose levels. In contrast, we find a strong negative correlation 
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between inflammatory markers and soluble adhesion molecules, implying that these 
values are a later consequence of the meal and may not be driving forces behind elevated 
blood glucose in T2DM. 
We did not find a significant difference in trypsin activities, inflammation 
markers, and soluble adhesion molecules in circulation between T2DM and control 
participants. The relatively high trypsin activity levels found in control participants 
(Figure 2.3C) may be due to their relatively high BMI and waist circumference, which 
are the only anthropometric characteristics with a positive correlation to trypsin activity 
values in circulation in controls (Figure 2.8). This may help explain why control fasting 
participants, who on average had the lowest BMI and waist circumference (Table 2.1), 
had the lowest trypsin activity (Figure 2.3). In addition, trypsin activity levels were low 
and close to the detection limit of our electrophoretic assay, making it difficult to identify 
significant differences in activities between groups. Chronic inflammation is a hallmark 
of T2DM [2], and studies report elevation of inflammation markers CRP and SAA in 
T2DM [24-26]. A possible reason for the relatively high levels of CRP and SAA in 
control participants is their relatively high waist circumference and BMI (Table 2.1); 
high levels of CRP and SAA have been associated with high waist circumference and 
BMI [27-28]. Soluble adhesion molecules are derived from proteolytic cleavage of the 
membrane bound adhesion molecule [29]. Though the mechanisms controlling the 
shedding remain unclear, membrane bound proteases may cleave the extracellular portion 
of the adhesion molecules, releasing the extracellular fragments into the plasma as 
“soluble” peptide [29-30]. We expected the higher proteolytic activity found in T2DM to 
yield higher levels of soluble adhesion molecules. A possible reason for the relatively low 
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values in soluble adhesion molecules in T2DM may be that chronic elevation of 
proteolytic activity in circulation leads to further cleaving of the soluble adhesion 
molecules, degrading their antibody binding sites and preventing detection by the 
immunological technique used (ELISA).   
Future studies will include fasting p-T2DM and T2DM groups and a greater 
number of participants. A limitation of our novel electrophoretic assay is that although its 
specificity is high it is not absolute. It would be of interest to measure the insulin receptor 
in the cells derived from different patients directly, bypassing the need for incubation of 
cells from a healthy volunteer with patient plasma. Finally, it would of interest to 
normalize the meal with respect to the BMI of each of the participants as well to test 
other meals to elucidate the effects of macronutrients on intestinal permeability. The 
results of this pilot study suggest that blockage of elevated proteolytic activity in 
circulation may be a therapeutic target for T2DM. 
2.4 Conclusion 
In conclusion, the results provide new evidence for the hypothesis that the 
digestive system, and in particular pancreatic proteases, are driving the development of 
T2DM. Pancreatic proteases, which are normally compartmentalized inside the intestinal 
lumen, may be reaching the circulation due to an increase in intestinal permeability after 
a meal. In the systemic circulation pancreatic proteases can degrade biomolecules. In this 
report we showed that proteases could be responsible for the reduction of the ectodomain 
of the insulin receptor in cells, impairing glucose control. Many membrane receptors 
have extracellular domains that may be subject to cleavage by proteases, which could be 
the reason for the diversity of cell dysfunctions that accompany T2DM.  
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2.5 Materials and Methods 
2.5.1 Sample acquisition  
Samples were collected from 10 T2DM, 10 pre-T2DM and 14 normal patients (11 
received meal, and 3 fasted). Volunteers participated in the study after giving informed 
written consent according to the guidelines of the Review Board for Human Research 
Protections Program at the University of California, San Diego. The volunteers fasted for 
a minimum of 12 hours. An intravenous catheter was placed in the antecubital vein of the 
non-dominant arm. Blood was withdrawn into collection tubes containing lithium heparin 
and EDTA (Becton Dickinson). An initial blood sample was collected to serve as a 
baseline level. Anthropomorphic measurements, general information on the subjects, as 
well as diet and exercise data were collected (Table 2.1). 
2.5.2 Meal tolerance test study design  
A McDonald’s meal consisting of hot chocolate, orange juice, hash browns, and 
egg McMuffins with a total of 1,680 calories was served to the volunteers. Blood samples 
were collected postprandially at 15, 30, 45, 60, 120, 180, 240 and 300 minutes. Blood 
was drawn in 4mL lithium heparin tubes (60 USP units of lithium heparin, Becton, 
Dickinson and Company Medical Supplies), stored at 4oC, and used to measure protease 
activity within two hours.  An additional blood sample was drawn into an EDTA tube for 
plasma generation and measurement of inflammatory markers, soluble adhesion 
molecules, and glucose concentration.  
2.5.3 Metabolic syndrome index (MSI) 
In order to define a control population we used an adaptation of the proposed 
Metabolic Syndrome Index (MSI). This proposed MSI is a five-point scale that assigns 
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one point to each of the five metabolic syndrome components: waist circumference, 
blood pressure, triglycerides, high-density lipoprotein (HDL) cholesterol, and fasting 
blood glucose. Here we adapted the index with the measurements that we had collected 
for all participants and created a five-point MSI, which assigned one point for each of the 
following components: waist circumference, BMI, SBP, DBP, and fasting blood glucose. 
The MSI value is the sum of the scores assigned to each of the four components (Figure 
2.1). With a score between 3 and 5, four control participants were discarded from the 
analysis of the study.  
2.5.4 Protease activity assays 
Activities of MMP-2 and -9, elastase, and trypsin were measured in fresh whole 
blood samples of volunteers using the charge-changing protease substrates and 
electrophoretic method developed by our lab [10-12]. This method uses synthetic 
fluorescent peptides that are specifically cleaved by a protease; the peptides are originally 
negatively or neutrally charged; upon cleavage by the protease of interest, two fragments 
are produced, a negative one and a fluorescently labeled positive one, which allows for  
electrophoretic separation and detection in whole blood with no sample preparation 
(Figure 2.2). This method has been described in detail [10-12].  
2.5.5 Insulin receptor labeling   
Freshly isolated PBMC cells from a healthy volunteer were incubated with 
plasma from control fasting, control, p-T2DM and T2DM participants collected at 
different time points after the meal, or with spiked proteases (elastase, MMP-2, and 
trypsin). A 50µL PBMC suspension and 150µL plasma solution were incubated for 1 
hour at 37oC. The cells were then spread as a blood smear, fixed (10% formalin, neutral 
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buffered) and labeled with a primary antibody against the extracellular domain of the 
insulin receptor (sc-710 polyclonal antibody mapping to the N-terminus, Santa Cruz 
Biotech) followed by the biotin/avidin Vector TMB peroxidase enzyme substrate. The 
cell images were collected using a bright field microscope (40X and 60X objective) and 
digitally analyzed (NIH Image J 1.440) to determine light absorption as a measure of the 
surface density of the insulin receptor extracellular domain. 
2.5.6 Inflammatory markers and soluble adhesion molecules 
Whole blood was preserved with EDTA. Following centrifugation at 4 oC, plasma 
was stored at -80 oC until assayed. Circulating levels of C-reactive protein (CRP), serum 
amyloid A (SAA), soluble intercellular cell adhesion molecule-1 (sICAM-1) and soluble 
vascular cell adhesion molecule-1 (sVCAM-1) were determined by commercial ELISA 
(MSD, Rockville, MD). Intra- and inter-assay coefficients were <5%. 
2.5.7 Statistical analysis  
All measurements are presented as mean ± standard error (SEM). Differences in 
individual variables during the meal tolerance experiment were analyzed by one-way 
repeated measurements ANOVA significance (F value for differences across the 6 time 
points) with paired t-tests where a significant difference (p < 0.05) was found. Paired t-
tests were used for between group comparisons of the variables. Correlations were 
analyzed using Pearson linear correlation coefficients.  
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Figure 2.1. Metabolic syndrome index (MSI) calculation flow-chart. 
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Figure 2.2. Protease activity detection. (A) Charge-changing fluorescently labeled 
substrate sequences and cleavage sites. (B-E) Novel electrophoretic assay for protease 
activity detection. (B) 4µL of whole blood is combined with 4µL of charge-changing 
substrate designed to be cleaved by a target protease. (C) After a 30 min reaction, 6µL 
aliquots of reaction mixture are loaded into a polyacrylamide mini-gel. (D) Gel is run at 
500V for 10 minutes (E) Detection of fluorescence is carried out in a fluorescence 
scanner. 
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Figure 2.3. Protease baseline activity. (A-C) Mean baseline activity for (A) trypsin, (B) 
elastase, and (C) MMP-2/9-like activities. Activities were measured after mixing plasma 
with charge-changing peptide substrates for each protease followed by electrophoresis 
and fluorescent imaging (see Methods section). *p<0.05, **p<0.001 versus T2DM and 
#p<0.05, ##p<0.001 versus p-T2DM. (D-F) Calibration curves in 1X PBS spiked with 
different concentrations of (D) trypsin, (E) elastase, and (F) MMP-2 and MMP-9. 
 
 41 
 
Figure 2.4. Postprandial protease activity and glucose levels in circulation. (A) Level 
of MMP-2/9-like activity, (B) elastase-like activity, and (C) trypsin-like activity in 
control and control fasting participants after a meal. (D) Level of MMP-2/9-like activity, 
(E) elastase-like activity, and (F) trypsin-like activity in pre-T2DM and T2DM after a 
meal. Activities were measured after mixing plasma with charge-changing peptide 
substrates for each protease followed by electrophoresis and fluorescent imaging (see 
Methods section). *p<0.05 versus time 0 within group. (G-I) Linear correlation of blood 
glucose levels and (G) MMP-2/9-like activity (p<0.0001), (H) elastase-like activity 
(p<0.0001), and (I) trypsin-like activity (p<0.01). 
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Figure 2.5. Insulin receptor density in PBMC incubated with plasma. (A) 
Ectodomain insulin receptor density in PBMC incubated with PBS and baseline plasma 
from control, p-T2DM, and T2DM. **,••p<0.01. Incubation with 1X PBS versus control, 
p-T2DM, and T2DM plasma; ••p<0.01 for control plasma versus incubation with p-
T2DM and T2DM plasma; •p<0.05 for incubation with p-T2DM plasma when compared 
to cells incubated with T2DM plasma. (B-E) Density of insulin receptor label after 
incubation with plasma samples at different times after a meal and with 1X PBS as 
control. (B) Incubation with plasma from control fasting (n=2), (C) with plasma from 
control (n=3), **p<0.01 versus time 0, (D) with plasma from p-T2DM (n=3), **p<0.01 
versus time 0, and (E) plasma from T2DM (n=3). 
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Figure 2.6. Baseline values for inflammation markers and soluble adhesion 
molecules mean baseline (A) CRP and SAA (B) sI-CAM1 and sV-CAM1 in each group. 
*p<0.05 versus T2DM and #p<0.05 versus p-T2DM. 
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Figure 2.7. Postprandial inflammation marker levels (A) CRP, (B) SAA, (C) sICAM-
1 and (D) sVCAM-1 levels in control and control fasting. (E) CRP, (F) SAA, (G) 
sICAM-1 and (H) sVCAM-1 levels in p-T2DM and T2DM after a meal for 5 hours; 
*p<0.05 when compared to time 0 for control participants. (I-L) Linear correlation of 
blood glucose levels and (I) CRP (p<0.0001) (J) SAA (p<0.0001), (K) sICAM-1 
(p<0.0001), and (L) sVCAM-1 (p<0.0001). 
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Figure 2.8. Linear correlations of baseline protease activity levels and 
anthropometric characteristics of participants. (A) Table with Pearson correlation 
coefficient values for baseline protease activity values and baseline anthropometric 
characteristics of control participants. (B-C) Linear correlation of baseline trypsin 
activity values with (B) BMI and (C) waist circumference for control participants. 
*p<0.1 and **p<0.05 Pearson correlation coefficient. 
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Figure 2.9. Insulin receptor density changes with reaction time and protease 
concentration. (A) Insulin receptor density depletion over reaction time with plasma 
from control participants collected 45 minutes after meal consumption. (B) Insulin 
receptor density after incubation with 1X PBS and 5nM of trypsin, elastase, and MMP-2 
enzyme spiked in 1X PBS. 
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Table 2.1. Baseline characteristics of study participants. (mean±SEM) 
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Abstract 
Intestinal permeability, insulin resistance, and hypertension have been associated 
with the pathogenesis of schizophrenia. In this study we investigate circulating proteolytic 
activity of digestive pancreatic proteases that would indicate intestinal permeability and 
provide a possible mechanism for insulin resistance via proteolytic cleavage of the 
ectodomain of the insulin receptor. We utilize a novel method for the detection of protease 
activities directly in fresh human whole blood samples. The density of insulin receptor (IR) 
and low density lipoprotein receptor-related protein 1 (LRP1) on the surface of peripheral 
blood mononuclear cells (PBMC) incubated with plasma from schizophrenia patients and 
control volunteers served to indicate the possibility that circulating proteolytic activity is 
responsible for certain cell dysfunctions. Inflammatory biomarkers and soluble adhesion 
molecules were also measured in schizophrenia patients and control volunteers. 
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3.1. Introduction 
 
Schizophrenia is a severe chronic brain disorder with symptomatic onset in early 
adulthood that persists throughout life [3]. Schizophrenia affects approximately 0.5–1% of 
the world population with high heritability [9]. The diagnosis of schizophrenia remains 
subjective, based on interviews of the person and family members, as there are no empirical 
disease markers available [2]. There is a great clinical need for reliable diagnostic tests 
based on the identification of blood markers for schizophrenia. Such diagnostic tests would 
not only improve our understanding of the molecular characteristics underlying the disease 
processes of schizophrenia, but would also help diagnose the disease in the early-onset 
phase, identify disease subtypes, aid in predicting and monitoring treatment response and 
compliance, and identify novel drug targets. 
Patients with first-episode psychosis (FEP) have high risk of weight gain, glucose 
dysregulation and dyslipidemias during the early stages of illness [1]. For example, 
circulating insulin-related peptides are elevated in first-onset schizophrenia subjects with 
no relative difference in glucose levels [8]. This suggests that hyperinsulinemia may have 
a role in the development of schizophrenia and that measurement of these peptides may 
have utility in diagnosis or stratification of patients before antipsychotic treatment. 
Moreover, drugs that improve insulin action may represent a novel treatment strategy. 
Alterations of other metabolic biomarkers indicative of perturbations in glucoregulatory 
pathways have also been identified in schizophrenia patients. In addition, schizophrenia 
patients show increased prevalence of impaired glucose tolerance and metabolic syndrome, 
irrespective of whether they received antipsychotic treatment [10]. Such metabolic 
dysfunction coupled with evidence of intestinal permeability in schizophrenia patients 
	 54 
suggests that digestive enzymes leaking into the circulatory system may play a role by 
leading to low levels of autodigestion of cell surface receptors. 
In the general population, certain biomarkers are predictive of development of 
insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes. All these conditions 
are known co-morbidities of psychotic disorders [12]. However, previous studies have not 
investigated protease activity and cell receptor cleavage profiles in schizophrenia patients, 
which might be valuable in elucidating the possible role of unchecked circulating protease 
activity in the metabolic abnormalities of schizophrenia patients. 
3.2. Results 
3.2.1 Study participants 
This study is ongoing as of the submission of this dissertation, but so far 4 control 
volunteers, 17 schizophrenia patients, and 15 enrollees with blinded diagnosis have been 
enrolled in the study. Age, sex, body mass index (BMI), diagnosis, and other clinical 
variables including smoking and drug use were included in medical records for this study 
but were not made available prior to the submission of this dissertation. 
3.2.3 Circulating protease activity 
 There were no significant differences between the circulating proteolytic activities 
of trypsin, chymotrypsin, elastase, or MMP-2/9 in the whole blood of schizophrenia 
patients (n=17) versus control volunteers (n=4) (Figure 3.1, Figure 3.2). Significant 
correlations may become apparent once the blinded diagnoses of the other study enrollees 
(n=15) become available. 
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3.2.3 Inflammatory markers and soluble adhesion molecules 
 Significant linear correlations were observed between various inflammatory 
markers and soluble adhesion molecules (Figure 3.3). A significant linear correlation 
occurred between MMP-2/9 activity and the inflammatory marker interleukin 6 (IL-6) 
(Figure 3.4). 
3.3. Discussion 
Molecular studies of chronic schizophrenia patients can be confounded since 
routinely used antipsychotic medications have several side effects, such as dysregulated 
glucose homeostasis. We were unable to circumvent this problem since our analyses of 
blood and plasma samples were not exclusively from first-onset, antipsychotic naïve 
patients. Recruitment of such patients is challenging, as large clinics diagnose only 20–30 
such patients each year and few centers follow standard operating procedures for sample 
collection. Once we have full demographic data on the patients enrolled in this study we 
will attempt to match control subjects for age, gender, BMI and smoking [13]. 
One major confounder in this study that may frustrate the elucidation of the role of 
circulating protease activity in the pathogenesis of schizophrenia is the elevation of 
proteolytic activity associated with smoking. According to a study in hospital outpatients, 
70% to 90% of patients with schizophrenia use nicotine. Heavy smokers (more than 20 
cigarettes per day) had 4 times the risk for multiple substance abuse. Many patients with 
schizophrenia are recreational cannabis users, and cannabis has a known effect on 
glucoregulation; thus we examined this potential confounding factor very closely. One 
study found that recent cannabis use was associated with a significant reduction in serum 
glucose. These patients absorb nicotine more effectively and efficiently, leading to 
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increased nicotine levels in the body. High nicotine levels also increase P450 enzyme 
activity, resulting in the necessity of higher dose neuroleptics for effective treatment [14].  
Other studies have shown that while drug-naïve patients with first-onset 
schizophrenia cluster very tightly together according to metabolomic profiles, a small 
number of samples did not [14]. These outliers may indicate the existence of schizophrenia 
subgroups, and it will be of interest to explore whether clinical parameters, such as disease 
progression, severity, and/or drug response relate to distinct proteolytic activity signatures. 
Although the sample size of this study is too small to make assumptions about patient 
subgroups, once enrollees with blinded diagnoses have their medical records revealed we 
hope to begin analyzing the enrolled patients for subgroups. Future studies with larger 
sample sizes over longer periods of follow-up are needed for deriving and validating 
diagnostic models for the identification of subjects at highest risk of metabolic co-
morbidities and for the prediction of their metabolic outcomes. 
3.4. Conclusion 
 
These early results need to be tested in larger studies and confirmed before their 
clinical relevance will be known. It will be important for such follow-up studies to involve 
patients with other psychiatric diseases (not just schizophrenia), to see whether the 
biomarkers are specific to schizophrenia or whether they indicate a broader range of 
psychiatric diseases. 
3.5. Materials and Methods 
3.5.1 Study population 
The Institutional Review Board of the University of California, San Diego reviewed 
and approved all human protocols. Human blood was obtained with informed consent from 
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healthy volunteers (n=4), schizophrenia patients (n=17), and enrollees with blinded 
diagnosis (n=15). 
3.5.2 Sample acquisition 
Blood (approximately 7.5 mL) was obtained from the forearm vein via 
venipuncture and drawn in lithium heparin-containing tubes and EDTA-containing tubes. 
Blood was kept at 4 °C from the time of venipuncture until it could be assayed (within 2 
hours of venipuncture) and processed into plasma and frozen immediately at –80 °C. 
3.5.3 Protease activity assays 
Activities of MMP-2 and -9, elastase, trypsin, and chymotrypsin were measured in 
fresh whole blood samples of volunteers using the charge-changing protease substrates and 
electrophoretic method developed by our lab [5-7]. This method uses synthetic fluorescent 
peptides that are specifically cleaved by a protease; the peptides are originally negatively 
or neutrally charged; upon cleavage by the protease of interest, two fragments are 
produced, a negative one and a fluorescently labeled positive one, which allows for  
electrophoretic separation and detection in whole blood with no sample preparation 
(Figure 3.1). This method has been described in detail [5-7].  
3.5.4 Insulin receptor labeling 
Freshly isolated PBMC cells from a healthy volunteer were incubated with plasma 
from control fasting, control, p-T2DM and T2DM participants collected at different time 
points after the meal, or with spiked proteases (elastase, MMP-2, and trypsin). A 50µL 
PBMC suspension and 150µL plasma solution were incubated for 1 hour at 37oC. The cells 
were then spread as a blood smear, fixed (10% formalin, neutral buffered) and labeled with 
a primary antibody against the extracellular domain of the insulin receptor (sc-710 
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polyclonal antibody mapping to the N-terminus, Santa Cruz Biotech) followed by the 
biotin/avidin Vector TMB peroxidase enzyme substrate. The cell images were collected 
using a bright field microscope (40X and 60X objective) and digitally analyzed (NIH 
Image J 1.440) to determine light absorption as a measure of the surface density of the 
insulin receptor extracellular domain (Figure 3.6). 
3.5.5 LRP1 receptor labeling 
Freshly isolated PBMC cells from a healthy volunteer were incubated with plasma 
from control fasting, control, p-T2DM and T2DM participants collected at different time 
points after the meal, or with spiked proteases (elastase, MMP-2, and trypsin). A 50µL 
PBMC suspension and 150µL plasma solution were incubated for 1 hour at 37oC. The cells 
were then spread as a blood smear, fixed (10% formalin, neutral buffered) and labeled with 
a primary antibody against the extracellular domain of the LRP1 receptor (sc-450 
polyclonal antibody mapping to the N-terminus, Santa Cruz Biotech) followed by the 
biotin/avidin Vector TMB peroxidase enzyme substrate. The cell images were collected 
using a bright field microscope (40X and 60X objective) and digitally analyzed (NIH 
Image J 1.440) to determine light absorption as a measure of the surface density of the 
insulin receptor extracellular domain (Figure 3.6). 
3.5.6 Inflammatory markers and soluble adhesion molecules 
Whole blood was preserved with EDTA. Following centrifugation at 4 oC, plasma 
was stored at -80 oC until assayed. Circulating levels of C-reactive protein (CRP), serum 
amyloid A (SAA), soluble intercellular cell adhesion molecule-1 (sICAM-1) and soluble 
vascular cell adhesion molecule-1 (sVCAM-1) were determined by commercial ELISA 
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(MSD, Rockville, MD). Intra- and inter-assay coefficients were <5%. Assays were 
performed in triplicate (Figure 3.4, Figure 3.5). 
3.5.7 Statistical Analysis 
ANOVA, ANCOVA, and Pearson linear correlations were performed on the data 
using SPSS software. 
Acknowledgments 
This work is funded by a project fellowship from UC San Diego Frontiers of 
Innovation Scholars Program (FISP). 
Chapter 3, in part, is currently being prepared for submission for publication of the 
material. Jamie Joseph, Elaine A. Skowronski, Augusta E. Modestino, Geert W. Schmid-
Schönbein, Michael J. Heller, Colin A. Depp, Dilip V. Jeste. “Pilot study of circulating 
proteolytic activity and proteolytic receptor cleavage in schizophrenia and comparison 
groups.” The dissertation author was the secondary investigator and secondary author of 
the material being prepared for submission for publication. The dissertation author 
designed and ran protease activity assays and receptor cleavage assays, analyzed data, and 
composed the text and figures of this chapter. 
 
 
 
 
 
 
 
	 60 
 
Figure 3.1. Protease activity detection. (A) Charge-changing fluorescently labeled 
substrate sequences and cleavage sites. (B-E) Novel electrophoretic assay for protease 
activity detection. (B) 4µL of whole blood is combined with 4µL of charge-changing 
substrate designed to be cleaved by a target protease. (C) After a 30 min reaction, 6µL 
aliquots of reaction mixture are loaded into a polyacrylamide mini-gel. (D) Gel is run at 
500V for 10 minutes (E) Detection of fluorescence is carried out in a fluorescence scanner. 
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Figure 3.2. Protease activity in circulation. Clustering of control, schizophrenia, and 
diagnosis blinded patients according to the proteolytic activities measured in whole blood. 
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Figure 3.3. Mean of protease activity in circulation. No significant difference was seen 
between circulating proteolytic activities for control group and schizophrenia patients. 
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Figure 3.4. Pearson linear correlations for inflammatory markers and soluble 
adhesion molecules. Significant linear correlations were found for certain pairs of 
inflammatory markers and soluble adhesion molecules across control group and 
schizophrenia patients. 
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Figure 3.5. Pearson linear correlation for proteases and inflammatory markers. Of 
the proteases and inflammatory markers and soluble adhesion molecules, only circulating 
MMP-2/9 activity and interleukin-6 concentration showed significant linear correlation. 
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Figure 3.6. Density of cell receptors exposed to proteolytic activity. Cells were 
incubated with the plasma of schizophrenia patients (red) or the plasma of control group 
(blue). Staining with labeled antibodies specific to the cell receptors of interest revealed 
the degree to which the plasma incubation cleaved the ectodomains of the insulin receptor 
(IR) and the low density lipoprotein receptor-related protein 1 (LRP1). 
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Abstract 
 
 
 The intestine of premature neonates is not fully mature and may be permeable to 
digestive enzymes. In this study we monitored the circulating proteolytic activities of 
neonates and related this activity to the length of stay of patients in the neonatal intensive 
care unit (NICU). In addition to investigating the leakage of pancreatic proteases into the 
circulation, we also monitored the coagulation protease thrombin in the circulation. 
Coagulation dysregulation has been associated with severe inflammation, such as that 
caused by sepsis, and since premature neonates are at higher risk of sepsis, coagulation 
proteolytic activity was of interest. 
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4.1. Introduction 
 
The advances in perinatal care over the last two decades have led to an improvement 
of neonatal survival worldwide [1, 2]. Adequate parenteral and enteral nutrition is 
associated with better outcomes for preterm infants [3]. Early introduction and rapid 
achievement of full enteral feeding (FEF) is a priority in the nutritional management of 
preterm infants, because it reduces the need for central venous catheters (CVCs) and thus 
the risk of infection and also reduces the length of hospital stay [4].  
The need to attain FEF rapidly often conflicts with the physiologic immaturity of 
the GI function of preterm infants and also with the occurrence of various comorbidities in 
the neonatal period [10]. In this perspective, we focus on length of stay (LOS) of neonates 
in the neonatal intensive care unit (NICU) and whether LOS is associated with clinical 
variables and circulatory biomarkers for gastrointestinal immaturity and permeability [8]. 
We deploy novel protease activity assays to measure circulating proteolytic activity of 
pancreatic proteases as well as matrix metalloproteinases associated with tissue 
remodeling. 
In addition to gastrointestinal immaturity, preterm infants also have a good 
hemostasis that is not reflected in conventional clotting tests such as prothrombin (PT) and 
partial thrombin time (PTT) using strong activators of clotting [9]. This is important to 
consider when pathological tests are obtained in neonates with bleeding complications or 
prior to invasive procedures. It may also be important for the definition of adequate doses 
of anticoagulants. The aim of the present study is to elucidate the role that some prenatal, 
neonatal and early postnatal variables play in favoring or delaying the achievement of 
 71 
stable thrombin activity levels and to determine whether time to this achievement 
influences the LOS in the NICU. 
4.2. Results 
4.2.1 Study participants 
 This pilot study is ongoing but as of the submission of this dissertation has assay 
the blood of 8 neonates in the neonatal intensive care unit (NICU) after obtaining parental 
consent. Clinical variables including sepsis diagnosis and gestational age were provided 
after testing was completed for each patient (Figure 4.1, Figure 4.2). 
4.2.2 Circulating protease activity 
 Protease activity was elevated mostly early in life and decreased with age, possibly 
reflecting the maturing of the intestinal lining with age (Figure 4.3). 
4.3. Discussion 
This study is the first to evaluate the effects of gestational age on circulating 
protease activity in neonates. Various prenatal, neonatal, and postnatal variables must also 
be considered when evaluating differences between circulating proteolytic activity of 
neonatal patients. Any clinical variable that disrupts adequate intestinal blood flow will 
most likely negatively impact the integrity and proper functioning of the intestine and in 
turn the proper containment of powerful digestive enzymes such as pancreatic proteases. 
Patent ductus arteriosus (PDA) impacts blood flow to vital organs in premature infants 
and the presence of symptomatic PDA has been associated with numerous adverse clinical 
outcomes, including impaired feeding tolerance and necrotizing enterocolitis. The 
increased flow of blood through the lungs also can reduce blood flow to the rest of the 
body. This can damage other organs, especially the intestines and kidneys [9]. 
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Our data suggest that there are clinical effects associated with increases in circulating 
protease activity in preterm neonates (Figures 4.4, 4.5, 4.6). Additional studies, confirming 
these findings and powered sufficiently to determine the association between circulating 
protease activity and the incidence of necrotizing enterocolitis are required. 
A limiting factor in our study is the lack of exclusion criteria. It would be prudent to 
exclude neonates exposed to external variables potentially affecting circulating protease 
activity, e.g. protease inhibitor administration. 
4.5. Materials and methods 
4.5.1 Study design 
The study protocol was approved by the institutional review board of the University 
of California, San Diego. From 2016 to 2017, we conducted a pilot study at University of 
California, San Diego Hillcrest Medical Center. In newborns and infants who needed 
intensive care, we monitored circulating protease activity. The primary endpoints of the 
study were morbidity. Measures of morbidity assessed were length of stay (LOS) in the 
neonatal intensive care unit (NICU); number of septic episodes; and hepatic damage as 
assessed by liver function tests. All physicians and nurses involved in the patients’ care 
were blinded to all assay results. All researchers involved in running assays were blinded 
to all clinical information concerning patients. 
4.5.2 Patients 
Provided parental consent was obtained, patients admitted to the neonatal intensive 
care unit at the University of California, San Diego Hillcrest Medical Center were enrolled 
if they fulfilled all of the inclusion criteria and none of the exclusion criteria. Inclusion 
criteria were gestational age >20 weeks and age ≤1 year. Exclusion criteria were an inborn 
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error of metabolism, an immunodeficiency or a disease that entailed impaired growth (other 
than dysmaturity), the use of corticosteroid drugs, preexistent life expectancy less than 6 
months. 
4.5.3 Protease activity assays 
Protease activity assays were performed on scavenged whole blood samples taken 
for complete blood count (CBC) testing of neonates. These scavenged samples were taken 
at different times of day, were not exclusively fasting or non-fasting. To obtain some 
information about thrombin generation in neonates in vivo, we investigated thrombin 
generation in shed blood from capillary incisions in neonates [5-8] (Table 4.1). 
4.5.4 Length of stay 
Length of stay in the NICU was expressed in days and calculated as the difference 
between the date of discharge and the start of NICU admittance. 
4.5.5 Septic episodes 
The Centers for Disease Control and Prevention criteria for nosocomial infections 
were used to identify septic events. For septic events to be taken into account, positive 
blood cultures were mandatory. Primary and secondary bloodstream infections were 
grouped together as “sepsis.” 
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Figure 4.1. Neonate sample acquisition and length of testing. 
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Figure 4.2. Gestational age and length of stay in the neonatal intensive care unit. 
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Figure 4.3. Time course of circulatory protease activity in neonates. 
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Figure 4.4. Activity of pancreatic proteases. 
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Figure 4.5. Activity of MMP-2/9 and thrombin. 
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NN013 Adrenal insufficiency, 
hyperglycemia, 
hypoglycemia, PDA 
Klebsiella infection, 
Sepsis 
Aspiration of 
formula, 
Surgery for PDA 
NN016 IUGR, PDA Staph, Sepsis ruled 
out 
Surgery for PDA 
NN017 IUGR, SGA, hypoglycemia None reported Surgery: none 
NN018 IDM, Hernias: bilateral 
inguinal, PDA 
Staph, Sepsis Surgery: hernia 
repair 
NN019 Hypoglycemia, PDA Sepsis ruled out Surgery: none 
NN020 Hypoglycemia, PDA Sepsis ruled out Surgery: none 
NN021 Hypoglycemia, PDA Sepsis ruled out Surgery: none 
Figure 4.6. Proteolytic activity with diagnoses of neonates. 
 
 
 
 
 
 
 
 
 
 
 80 
Table 4.1. Peptide substrates for protease activity detection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Protease  Charge-Changing Fluorescent Peptide Sequences and Cleavage Site
Charge 
Substrate CleavageProduct
Trypsin Ac-N-Asp
––Gly–Asp––Ala–Gly–Arg+// 
Ala–Gly–Ala–Gly–Lys(ε-BFL)-NH2 -1 +1
Elastase Ac-N-Asp
––Ala//Gly//Ser–Val//
Ala//Gly//Ala//Gly–Lys(ε-BFL)-NH2 -1 +1
MMP-2/9 Ac-N-Gly–Asp
––Leu–Ala–Ala–Ile//
Thr–Ala–Ala–Gly–Ala–Gly–Lys(ε-BFL)-NH2 -1 +1
Chymotrypsin Ac-N-Asp
––Gly–Asp––Ala–Ala–Tyr//
Ala–Ala–Tyr–Ala–Gly–Ala–Gly–diaminoethyl-BFL -2 +1
Thrombin Ac-N-Asp
––Asp––Nle–Thr–Pro–Arg+
//Gly-Ser-Ala-Gly-Ala-Gly-Ala-Gly-diaminoethyl-BFL -1 +1
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